Comments
Serum Institute of India (SII) has got the Drug Controller General of India’s go-ahead to increase the shelf-life of its Covid-19 vaccines from six to nine months.
SII makes and supplies the AstraZeneca-OxfordUniversity vaccine in several low- and middle-income countries, and the increased shelf-life comes at a time when there is pressure on supplies of the vaccine.
The approval to increase the shelf-life period was received in February, a person familiar with the development told Business Line . It comes on the back of fresh data on the stability of the vaccine over a longer period, the person said. This would be reviewed again in about three months, and depending on the data, the company could approach the DCGI to extend the shelf-life for a year, the person added.
Recently, reports from South Africa had indicated concern over vaccine stocks facing expiry. The latest development gives a fresh insight on the product that is the same, even as its labelling is now being changed to reflect the extended shelf-life.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.